A Common Factor Links Mechanisms of Acquired Resistance to Melanoma Treatment

Share this content:
Inhibition of ER translocation prevented both ERK reactivation and autophagy, suggesting a potential strategy for improving BRAF and MEK inhibition therapy outcomes.
Inhibition of ER translocation prevented both ERK reactivation and autophagy, suggesting a potential strategy for improving BRAF and MEK inhibition therapy outcomes.

In their experiments, BRAFi + MEKi treatment-induced ER translocation in melanoma triggered ERK reactivation. That, in turn, increased autophagy.1 Because ER translocation happens so rapidly after BRAFi + MEKi, Dr Amaravadi said he believes the drugs are directly inducing ER translocation.

“Our study involved genetic manipulation of genes to prove the pathway is required for ER translocation,” Dr Amaravadi said. “But in melanoma cells, the components of these pathways are not mutated at the genomic level. The implication of our work is that we found a complex pathway that regulates ER translocation of the MAPK pathway and many steps in this pathway involve druggable enzymes.” 



“We used genetic inhibition of key genes that control ER translocation of the MAPK pathway following BRAF and MEK inhibition to demonstrate that targeting this pathway can enhance the efficacy of BRAF and MEK inhibitors,” including grp78, KSR2, SEC61 and the PERK enzyme, Dr Amaravadi explained. “In each case, the efficacy of BRAF and MEK inhibitor therapy in cell lines was augmented.”

“Ultimately, ER translocation promotes ERK reactivation, which turns on autophagy through ATF4,” he said. “When ATF4 was inactivated in targeted therapy-resistant, patient-derived xenografts, these tumors suddenly responded to BRAF and MEK inhibition in vivo.”

“Examination of a number of tumor samples from therapy-resistant patients from multiple institutions found that this pathway was almost always activated in the resistance samples, underscoring the point that this resistance mechanism could apply to the vast majority of melanoma patients treated with targeted therapy,” he said.

The research team concluded that “the combination of an ERK inhibitor with BRAFi + MEKi could be effective.” The team is planning to conduct additional studies zeroing in on earlier pathways of ER translocation, Dr Amaravadi said.

References

  1. Ojha R, Leli NM, Onorati A, et al. ER translocation of the MAPK pathway drives therapy resistance in BRAF mutant melanoma [published online December 18, 2018]. Cancer Discov. doi: 10.1158/2159-8290.CD-18-0348
  2. Meierjohann S, Schilling B. BRAF-mutant melanoma: treatment approaches and resistance mechanisms. In: Dammacco F, Silvestris F, eds. Oncogenomics: From Basic Research to Precision Medicine. London, United Kingdom: Academic Press; 2019:669-698.
Page 2 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs